Z Squared Inc. quarterly report, Q3 FY2025

Business Context and Reporting Period

Company: Coeptis Therapeutics Holdings, Inc. (trading symbol: COEP)

Filing Type: Form 10-Q (Unaudited)

Reporting Period: Quarter and nine months ended September 30, 2025

Business Overview: Coeptis operates as a holding company with two primary segments: Biotechnology (developing cell therapy platforms for cancer and autoimmune diseases, including GEAR and SNAP-CAR technologies) and Technology (AI-powered marketing and automation via the NexGenAI platform). The company is a smaller reporting company and an emerging growth company.

Key Financial Metrics

Metric Q3 2025 (3 Months) Q3 2024 (3 Months) YTD 2025 (9 Months) YTD 2024 (9 Months)
Total Revenue $237,441 $0 $500,996 $0
Gross Profit $192,286 $0 $365,528 $0
Net Loss $(2,898,763) $(1,828,914) $(10,654,290) $(7,865,647)
Loss Per Share (Basic/Diluted) $(0.58) $(0.05) $(2.69) $(0.21)
Cash and Equivalents (End of Period) $4,908,487 (Sep 30, 2025) vs. $532,885 (Dec 31, 2024)
Total Assets $14,181,641 (Sep 30, 2025) vs. $8,908,660 (Dec 31, 2024)
Total Liabilities $3,264,864 (Sep 30, 2025) vs. $5,041,434 (Dec 31, 2024)
Stockholders' Equity $10,916,777 (Sep 30, 2025) vs. $3,867,226 (Dec 31, 2024)

Material Changes vs. Prior Period

  • Revenue Generation: The company generated revenue for the first time in the reported periods, totaling $500,996 YTD 2025, driven entirely by the Technology segment (lead generation and webinar services). The prior year periods had zero revenue.
  • Liquidity Improvement: Cash balances increased significantly from $532,885 at year-end 2024 to $4,908,487 at September 30, 2025. This was driven by a net cash inflow of $11.3 million from financing activities, including a $5.0 million private placement and proceeds from the Standby Equity Purchase Agreement (SEPA).
  • Debt Reduction: The company satisfied several convertible notes, including the Yorkville notes (YA Note-1 and YA Note-2) and the Purple Biotech note, through conversion to equity or cash repayment. Convertible notes payable dropped from $1.1 million (net of discount) in Dec 2024 to $0 in Sep 2025.
  • Operating Expenses: Operating expenses increased to $11.4 million YTD 2025 from $7.9 million YTD 2024. This increase was primarily due to higher professional services fees related to a pending merger and increased stock-based compensation. However, R&D expenses decreased due to the termination of a Shared Services Agreement with Deverra Therapeutics.
  • Derivative Liabilities: The company recognized a gain of $856,180 YTD 2025 from the change in fair value of derivative liabilities, largely due to the extinguishment of the SEPA derivative liability and changes in warrant valuations.

Guidance, Outlook, Risks, and Unusual Items

  • Pending Merger: On April 25, 2025, Coeptis entered into a Merger Agreement to acquire Z Squared, Inc. The transaction involves a spin-out of Coeptis's biotechnology operations to existing shareholders, with Z Squared becoming a wholly-owned subsidiary. Closing is expected in late 2025 or Q1 2026.
  • Going Concern: The filing states that the company's accumulated deficit of $108.4 million and net losses raise substantial doubt about its ability to continue as a going concern. Management plans to raise additional capital through equity or debt to sustain operations.
  • Unusual Items:
    • Unrealized Losses: The company recorded an unrealized loss of $568,868 in Q3 2025 on marketable securities (publicly traded stock received as payment for services).
    • Non-Cash Transactions: Significant non-cash financing activities included the conversion of debt to equity ($2.4 million) and the satisfaction of subscription receivables via the assignment of shares in privately held companies.
  • Risk Factors: Risks include the failure to successfully develop a profitable business, inability to retain customers, and the uncertainties associated with the pending merger and spin-out transaction.

Investor Verification Checklist

  • Merger Status: Verify the progress and regulatory approval status of the Z Squared merger and the biotechnology spin-out.
  • Cash Burn Rate: Assess the sustainability of the current cash position ($4.9M) against the high operating burn rate (approx. $3.5M net loss in Q3 alone) and the timeline to profitability.
  • Revenue Quality: Confirm the recurring nature of the Technology segment revenue and the concentration risk (100% of revenue came from three customers in Q3).
  • Debt Obligations: Review the terms of the remaining $150,000 SBA loan and the $100,000 notes payable currently in default.
  • Related Party Transactions: Scrutinize the investments in privately held companies where the CEO and CFO hold ownership interests, and the valuation of these assets.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.